AI-generated · cited to primary sources · not investment advice · How we research
Fortis Health.
Our verdict on Fortis Health. isn’t the consensus take — see where we landed, and the one risk the bull case glosses over.
See the verdict — free →Does management do what it says?
The company has achieved a 300 basis point improvement in consolidated operating EBITDA margins for the 9-month period, surpassing the full-year target of 200 bps. (1 exceeded, 1 met across 2 tracked commitments)
“As we have guided earlier also, it was -- the margins for -- if you see the half year, we are around 24%. So I think we'll be somewhere around the 23%, 24% for the whole year is what we are expecting.”
The Manesar facility achieved EBITDA positive status in less than one year, ahead of previous expectations. (1 exceeded, 3 met across 4 tracked commitments)
“I am expecting if we're able to achieve the revenue of INR2 crores more per month, which we are expecting in the next couple of months, this unit should be breakeven on EBITDA level.”
See the full cited Management analysis of Fortis Health.
How durable is the business?
The hospital business remains the dominant engine, growing 14.8% for the full year FY25, driven by higher occupancy and ARPOB expansion. (2 expanding)
“Hospital business revenues grew 14.8% to INR 6,528. Operating margins stood at 20.5% versus 18.6% in FY24.”
The hospital business remains the primary engine, with revenue growing 14.8% and EBITDA margins expanding from 18.6% to 20.5% for the full year FY25. (2 expanding)
“Our hospital business revenues have grown 14.8% to INR 6,528 crores... hospital business operating EBITDA margins have improved from 18.6% to 20.5% in financial year '25.”
See the full cited Business Model analysis of Fortis Health.
Where does growth come from?
Fortis is entering a massive brownfield expansion cycle, planning to add approximately 2,000 beds from FY26 to FY29, with a significant 993-bed addition scheduled for FY26 alone. (5 accelerating across 5 signals, 2 leading indicators)
“During the year so far, we have added approximately 750 operational beds... The bed addition also accounts for our Jalandhar acquisition, Greater Noida lease facility and expansion in our existing facilities”
Fortis is aggressively pursuing inorganic growth in the Punjab region, acquiring Shrimann Superspecialty Hospital with potential to expand to 450 beds. (3 new trend across 3 signals, 1 leading indicator)
“in January 2026, we acquired the 125-bedded People Tree Hospital in Yeshwanthpur, Bengaluru for INR430 crores... enables future expansion to over 300 beds within the same location.”
See the full cited Future Growth analysis of Fortis Health.
What could break the thesis?
Net debt has increased further to INR 1,869 Cr from INR 1,694 Cr in the previous quarter (March 2025). The Net Debt to EBITDA ratio has risen to 0.92x compared to 0.22x a year ago, driven by the acquisition of the 31.5% stake in Agilus Diagnostics and the 'Fortis' brand. (3 intensifying, 2 easing, 2 high-severity)
“The decline in PAT was primarily due to the one-off expense for the quarter INR55 crores pertaining to New Labour Codes”
While specific 'Gleneagles' branding was not the focus, management highlighted that they have successfully acquired the 'Fortis' brand and trademarks, which removes the royalty drag and provides brand stability. However, some facilities like Vashi still face clinician attrition issues. (1 stable, 1 easing, 1 intensifying)
“Nine months growth is actually negative for the unit we are looking at. It is almost 4% negative. And there are a lot of disturbance. There is clinician attrition.”
See the full cited Risk analysis of Fortis Health.
Read the full thesis on Fortis Health.
AI-generated informational research only. ThesisLoop is not investment advice, a stock recommendation, or a guarantee of returns.